Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein

Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.

(2017) W. Tan et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors.

(2017) C. Li et al.   JOURNAL OF CLINICAL ONCOLOGY

An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Reduces Tumor Burden and Metastasis in a Preclinical Model of Ovarian Cancer Metastasis

(2015) Marion Zillhardt et al.   NEOPLASIA

Guide to Receptors and Channels (GRAC), 5th edition

(2011) SPH Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer

(2011) K. Takezawa et al.   CLINICAL CANCER RESEARCH

Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?

(2011) Anna Brózik et al.   Expert Opinion on Drug Metabolism & Toxicology

Gender Specific Drug Metabolism of PF-02341066 in Rats — Role of Sulfoconjugation

(2010) Wei-Zhu Zhong et al.   CURRENT DRUG METABOLISM

Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function

(2009) Li-yang Tao et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2

(2009) Chun-ling Dai et al.   CANCER LETTERS

Vandetanib (Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function

(2009) Li-sheng Zheng et al.   PLoS One

Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1®

(2008) Robert W. Robey et al.   BIOCHEMICAL PHARMACOLOGY

Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

(2008) C.-l. Dai et al.   CANCER RESEARCH

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

(2008) D. B. Costa et al.   CLINICAL CANCER RESEARCH